Vaccines against Ovine Toxoplasmosis: History, Advances and Current status


Rawaz Mhamad Jaza Sulaiman
MSc.Biomedical Sciences, Sulaimani Veterinary Directorate, Sulaimani





Abstract
Toxoplasmosis is a common and wide spread global disease, caused by a protozoan parasite,
Toxoplasma gondii. The condition afflicts both animal and human, causing abortion and congenital
defects. Hence, it is of a huge veterinary and medical concern. With on-going researches, the
mechanism of the disease is better appreciated nowadays. Developing a vaccine for veterinary use,
more precisely for sheep will not only gain economic advantages, but it will also bring insight into
discovering one for human use as well. Until now, the only available commercial vaccine in sheep is
based on the attenuated T.gondii strain S48, known as Toxovac®, but the vaccine is only capable to
provide a short immunity. Additionally, it is expensive and inappropriate to be applied in human. In
recent years, different experimental studies have demonstrated the probability of developing a new
vaccine. This paper tries to highlight the history of discovering the first commercial vaccine against
toxoplasmosis in sheep, along with recent advances in the field and shining a light to the current
status of vaccine trials.

Keywords: Toxoplasmosis, Immunity against T.gondi, Vaccines in sheep, DNA vaccines.



References:

[1] DubeyJ.P. and BeattieC.P.,'' Toxoplasmosis in animals and man''In:
ElsheikhaH.M.''Congenital toxoplasmosis: priorities for further health promotion action''. Public
Health.122, pp. 335-353, (2008).
[2] Tizard I., ''Veterinary immunology''. 9th Ed. Elsevier. Texas. (2013).
[3] Edwards J. F. and Dubey J. P., ''Toxoplasma gondii abortion storm in sheep on a Texas farm
and isolation of mouse virulent atypical genotype T. gondii from an aborted lamb from a
chronically infected ewe''. Veterinary parasitology, 192, pp. 129-136, (2013).
[4] Dubey J. P., ''History of the discovery of the life cycle of Toxoplasma gondii'', International
journal of parasitology, 39, 877-882, (2009).
[5] Hill D.E. and Dubey.J. P, ''Toxoplasma gondii prevalence in farm animals in the united
states''. International journal for parasitology, 43, pp. 107-113, (2013).
[6] MontoyaJ.G. and Liesenfeld O., ''Toxoplasmosis''. The lancet, 363 (9425), pp.1965-1976,
(2004).
[7] Dubey.J. P., ''Toxoplasmosis in sheep-the last 20 years''. Veterinary parasitology, 163, pp.1-
14, (2009).
[8] KumarH., Kawai T., and Akira S., ''Toll-like receptors and innate immunity''. Biochemical
and Biophysical research communication, 388(4), pp. 621-625, (2009).
[9] Alberti J., and Bafica A., ''Anti-inflammatory pathways as a host evasion mechanism for
pathogens''. Prostaglandins, Leukotrienes and Essential Fatty Acids, 73, pp. 283-288, (2005).
[10] Ibrahim H. M., Xuan X., and Nishikawa Y., ''TosxoplasmagondiiCyclophilin 18 regulates
the proliferation and migration of murine macrophages and spleen cells”.Clinical and vaccine
immunology, 17(9), pp. 1322-1329, (2010).
[11] MillerC.M., BoulterN.R., IkinR.J., and Smith N.C., ''The immunobiology of the innate
response to Toxoplasma gondii''. International journal for parasitology, 39, pp. 23-39, (2009).
[12] Liu Q., Singla L.D., and Zhou H., ''Vaccines against Toxoplasma gondii''. Human vaccines
and immunotherapeutics, 8 (9), pp. 1305-1308, (2012).
[13] KurJ., Holec-GasiorL.andHiszcynska-Sawicka E., ''Current status of toxoplasmosis vaccine
development''. Experst Review Vaccine, 8(6), pp. 791-808, (2009).
[14] BillkerO., LouridoS., and SibleyL. D.,'' Calcium-Dependent signalling and Kinases in
Apicomplexian Parasites''. Cell host & Microbe, 5, 612-622, (2009).
[15] Innes E. A., Panton W. R., and Sanderson A., Thomson K. M. Wastling J. M. Maley S., and
Boxton D., ''Induction of CD4+ and CD8+ T cell responses in efferent lymph responding to
Toxoplasma gondii infection: analysis of phenotype and function''. Parasite immunology, 17, pp.
151-160, (1995).
[16] SuzueK., AsaiT., Takeuchi T., and Koyasu S., ''In vivo role of IFN- gamma produced by
antigenpresenting cells in early host defense against intracellular pathogens''. European journal of
immunology, 33, pp. 2666-2675, (2003).
[17] ZhouH., MinJ., ZhaoQ., Gu et al. ''Protective immune response against Toxoplasma gondii
elicited by a recombinant DNA vaccine with a novel genetic adjuvant''. Vaccine, 30, pp. 1800-
1806, (2012).
[18] O’connellE., Wilkins M. F., and PungaW. A., '' Toxoplasmosis in sheep. II. The ability of a
live vaccine to prevent lamb losses after an intravenous challenge with Toxoplasma gondii''.
Newzland veterinary journal, 36, pp. 1-4, (1988).
[19] Buxton D., ''Toxoplasmosis: the First Commercial Vaccine''. Parasitology Today, 9(9), pp.
335-337, (1993).
[20] Buxton D., Thomson K., Maley S., Wastling J. M., Innes E. A. Panton W. R., and Nicoll S.
''Primary and Secondary Responses of the Ovine Lymph Node to Toxoplasma gondii: Cell
Output in Efferent Lymph and Parasite Detection''. Journal of comparative pathology, 111, 231-
241, (1994).
[21] Buxton D., and Innes E., ''A commercial vaccine for ovine toxoplasmosis''.Parasitology, 110,
pp. S11-S16, (1995).
[22] Buxton D., Thomson K., Maley S., Wright S., and Bos H. J., ''Vaccination of sheep with a
live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when
pregnant''. The veterinary record, 129, pp. 89-93, (1991).
[23] Falcon J., and Freyre A., ''Toxoplasma gondii: prototype immunization of lambs against
formation of muscle and brain cyst''. Veterinary parasitology, 166, pp. 15-20, (2009).
[24] Araujo F., and Slifer T., ''Different Strains of Toxoplasma gondii Induce Different Cytokine
Responses in CBA/Ca Mice''. Infection and Immunity, 71(7), pp. 4171-4174, (2003).
[25] Freyre A., Falcon J., Mendez J., and Gonzalez M., ''Toxoplasma gondii: protection against
colonization of the brain and muscles in a rat model''. Experimental parasitology, 119, pp. 252-
255, (2008).
[26] Babiuk S., TsangC.,vanDrunen L. H. S. ''A single HBsAg DNA vaccination in combination
with electroporation elicits long-term antibody responses in sheep''. Biochemistry, 70, pp. 269-
274, (2007).
[27] HiszczynskaE., Li H.,Xu J. B., Oledzka G., Kur, J., Bickerstaffe R., and Stankiewicz M.,
''Comparision of immune response in sheep immunized with DNA vaccine encoding Toxoplasma
gondii GRA7 antigen in different adjuvant formulations''. Experimental Parasitology, 124, pp.
365-372, (2010).
[28] Hadad D., Bilcikova E., Witney A. A., Carlton J., White C. E., and Blair P. L., et al.''Novel
antigen identification method for discovery of protective Malaria antigens by rapid testing of
DNA vaccines encoding Exons from the parasite genome''. Infection and Immunity, 72(3), pp.
1594-1602, (2004).
[29] Gurunathan S., Sacks D. L., Brown D. R., Reiner S. L., Charest H., Glaichenhaus N., and
Seder R. A., ''Vaccination with DNAencoding the immunodominant LACK parasite antigen
confers protective immunity to mice infected with Leishmania major''. Journal of experimental
medicine,186, pp.1137–47, (1997).
[30] Min J., QuD., Li C., Song X, Zhoa Q., and Li X. A., et al., ''Enhancement of protective
immune responses induced by Toxoplasma gondii dense granule antigen 7(GRA7) against
toxoplasmosis in mice using a prime-boost vaccineation strategy''. Vaccine, 30, pp. 5631-5636,
(2012).
[31]Jongert E., de Craeye S., Dewit J., and Huygen K., ''GRA7 provides protective immunity in
cocktail DNA vaccines against Toxoplasma gondii''. Parasite immunology, 29, pp. 445-453,
(2007).
[32] SoldatiD., Dubremets J., and LebrunM., ''Microneme proteins: structural and functional
requirments to promote adhesion and invation by apicomplexian parasite Toxoplasma gondii''.
International Journal for Parasitology, 31, pp. 1293-1302, (2001).
[33] Tomely F., and SoldatiD., ''Mix and match modules: structure and function of microneme
proteins in apicomplexian parasites''. Trends in Parasitology, 17(2), pp. 81-88, (2001).
[34] IsmaelA. B., Sekkai D., CollinC.,Bout D., and Mevelec M.,'' The MIC3 Gene of Toxoplasma
gondii is a novel potent vaccine candidate against Toxoplasmosis''. Infection and Immunity,
71(11), pp. 6222-6228, (2003).
[35] Beghetto E., Niesen H. V., Del Porto P., Buffolano W., Guglietta S., Felici F., Petersen E.
and Gargano N.,''A combination of antigenic region of Toxoplasma gondiimiconeme proteins
induces protective immunity against oral infection with parasitic cysts''. The Journal of Infectious
Diseases, 191, pp. 637-645, (2005).
[36] Hiszczynska-Sawicka E., Li H., Bouu X., J., Akhtar M., Jolec-Gasior L., Bickersaffe R., and

Stankiewicz M., ''Induction of immune responses in sheep by vaccination with liposome-
enterapped DNA complexes encoding Toxoplasma gondii MIC3 gene''. Polish journal of

veterinary sciences, 15(1), pp. 3-9, (2012).
[37] Kim S., and Boothroyd J., ''Stage specific expression of surface antigens by Toxoplasma
gondiias a mechanism to facilitate parasite persistence''. Journal of immunology, 174 (12), pp.
8038-8048, (2005).

[38] Cesbron-DelauwM. F. and CapronA.. ''Excreted/secreted antigens of Toxoplasma gondii-
their origin and role in the host-parasite interaction''.Research in Immunology, 144(1), pp. 41-44,

(1993).
[39] Tomavo S., '' The major surface proteins of Toxoplasma gondii: Structure and functions''.
Current topics in Microbioology and Immunology, 219, pp. 45-54, (1996).
[40] Debard N., Buzoni-Gatel D., and Bout D., ''Intranasal immunization with SAG1 protein of
Toxoplasma gondii in association with cholera toxin dramatically reduces development of
cerebral cycts after oral infection''. Infection and Immunity, 64(6), pp. 2158-2166, (1996).
[41] Letscher-Bru V., Villard O.,Risse B., Zauke M., Klein J. P., and Kien T. T., ''Protective
effect of vaccination with a combination of recombinant surface antigen 1 and Interleukin-12
against Toxoplasmosis in mice''. Infection and Immunity, 66(9), pp. 4503-4506, (1998).
[42] AngusC. W., Klivinton-EvansD., Dubey J. P. and Kovacs J. A., ''Immunization with a DNA
plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective
in rodents''. Journal of Infectious Diseases, 181, pp. 317-324, (2000).
[43] Li B., Oledzka G.,McFarlane R. G., Spellerberg M. B., Smith S. M., Gelder F.B. Kur J.,
Stankiewicz M., ''Immunological responses of sheep to injections of plasmid encoding
Toxoplasma gondiiSAG1 and ROP1 genes''. Parasite Immunology, 32, pp. 671-683, (2010).
[44] Rodgers L., Wang X., Wen X., Dunford B., Miller R., and Suzuki Y., ''Strains of
Toxoplasma gondiiused for tachyzoite antigens to stimulate spleen cells of infected mice in vitro
affect cytokine responses of the cells in the culture''. Parasitology Research, 97(4), pp. 332-335,
(2005).
[45] Tilley M., Fichera M. E. Jerome M. E., Roos D. S., and White M. W., ''Toxoplasma
gondiisporozoites form a transient parasitophorous vacuole that is impermeable and contains only
a subset of dense-granule proteins''.Infection and immunity, 65(11), pp. 4598-4605, (1997).
[46] Supply P., Sutton P., Coughlan S. N., Bilo K., Saman E., Trees A. J., CesbronDelauw M. F.
and Locht C. ''Immunogenecity of recombinant BCG producing the GRA1 antigen from
Toxoplasma gondii''. Vaccine, 17, 705-714, (1997).
[47] Min J., QuD., Li C., Song X., Zhao Q., Li X. A., Yang Y., Liu Q., He S., and Zhou H.,
''Enhancement of protective immune responses induced by Toxoplasma gondii dense granule
antigen 7(GRA7) against toxoplasmosis in mice using a prime-boost vaccineation strategy''.
Vaccine, 30, pp. 5631-5636, (2012).
[48] Fischer h. G., Stachelhaus S., Sahm M., Meyer H. E., and Reichmann G., ''GRA7, an
excretory 25kDa Toxoplasma gondii dense granule antigen released by infected host cells''.
Molecular and Biochemical parasitology, 91, pp. 251-262, (1998).
[49] Hiszczynska-Sawicka E., OledzkaG., Holec-Gasior L., Li H., Xu J. B., Sedcole R., Kur J.,
Bickerstaffe R., Stankiewicz M., ''Evaluation of immune response in sheep induced by DNA
immunization with genes encoding GRA1, GRA4, GRA6 and GRA7 antigens of Toxoplasma
gondii''. Veterinary parasitology, 177, 281-289, (2011)
[50] Hyde S. C., Southern K. W., Gileadi U., Fitzjohn E. M. Mofford K. A. Waddell B. E., et al.,
''Repeat administration of DNA/liposome to the nasal epithelium of patients with cystic fibrosis''.
Gene therapy, 7, 1156-1165, (2000).
[51] Scorza T., Souza S., LaloupM., Dewit J., Breakeleer J. D. Verschueren H., et al., ''A GRA1
DNA vaccine primes cytolytic CD8+ T cells to control acute Toxoplasma gondii infection''.
Infection and Immunity, 71(1), 309-316, (2003).
[52] Vercammen M., Scorza T., HugenK., Braekeleer J. D. Diet R., Jacobs D., et al., ''DNA
Vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7, and ROP2 induces
partially protective immunity against lethal challange in mice''. Infection and Immunity, 68(1),
38-45, (2000).
[53] CarruthersV. B. and Sibley L. D., ''Sequential protein secretion from three distinct organelles
of Toxoplasma gondii accompanies invasion of human fibroblast''. European journal of
parasitology, 73(2), 114-123, (1997).
[54] Costa-Silva T. A., MeiraC. S., FerreiraI. M. Hiramoto M., and Pereira-Chiccola
VL.''Evaluation of immunization with tachyzoite excreted-secreted proteins in a novel
succeptible mouse model (A/Sn) for Toxoplasma gondii''.Experimental parasitology, 120, pp.
227.234, (2008).
[55] SafferL. D., Mercerau-PuijalonO., Dubremetz J. F. and Schwartzman J. D., ''Localization of
a Toxoplasma gondiirhoptry protein by immunoelectron microscopy during and after host cell
penetration''. Journal of protozoology, 39(4), 526-530, (1992).
[56] Dlugonska H., ''ToxoplsmaRhoptries: Unique secretory organelles source of promising
vaccine proteins for immunoprevention of Toxoplasmosis''. Journal of Biomedicine and
Biotechnology, pp. 1-7, (2008).
[57] Leyva R., HerionP., and Saavedra R., ''Genetic immunization with plasmid DNA coding for
the ROP2 protein of Toxoplasma gondii''. Parasitology research, 87(1), pp. 70-79, (2001).
[58] Mishima M., Xuan X., Yokoyama N., Igarashi I., Fujisaki K., Nagasawa H., and Mikami
Takeshi., ''Recombinant feline herpesvirus type 1 expressing Toxoplasma gondii ROP2 antigen
inducible protective immunity in cats''. Parasitology Research, 88(2), pp. 144-149, (2002).
[59] Zheng B., Lu S., Tong Q., Kong Q., and Luo D., ''The virulence-related rhoptry 5 (ROP5) of
Toxoplasma gondiiis a novel vaccine candidate against toxoplasmosis on mice''. Vaccine, 31, pp.
4578-4584, (2013).
[60] Yuan Z. G. Zhang X. X., He X. H., Petersen E., Zhou D. H. and Yong H., et al., ''Protective
immunity induced by Toxoplasma gondiiRhoptry protein 16 against Toxoplasmosis in Mice''.
Clinical and Vaccine Immunology, 18(1), pp. 119-124, (2011).
[61] Yuan Z. G. Zhang X. X. Lin R. Q. Petersen E., He S., and Yu M., et al.,''Protective effect
against toxoplasmosis in mice induced by DNA immunization with gene encoding Toxoplasma
gondii ROP18''. Vaccine, 29, pp. 6614-6619, (2011).